Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Zhejiang Huahai Pharmaceutical Co Ltd's Drug Receives Approval from FDA
Zhejiang Huahai Pharmaceutical Co Ltd announced that a kind of lamotrigine extended-release tablets, which is used for epilepsy, developed by Par Pharmaceutical and produced by the Company, received the approval from Foods and Drug Administration on January 19, 2013 and has been on sale in the United States since the same day.
Latest Developments for Zhejiang Huahai Pharmaceutical Co Ltd
- Zhejiang Huahai Pharmaceutical Co Ltd Receives Drug Registration Approval from State Food and Drug Administration
- Zhejiang Huahai Pharmaceutical Co Ltd Announces Cooperation with ONCOBIOLOGICS
- Zhejiang Huahai Pharmaceutical Co Ltd Announces Appointment of Chairman
- Zhejiang Huahai Pharmaceutical Co Ltd Announces FY 2012 Dividend Payment
Latest Key Developments in Pharmaceuticals
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet Against House Dust Mite Allergy
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- Share this
- Link this
- Digg this
Follow Reuters